NewsRamp provides syndicated and curated news distribution and marketing services for major newswires.
May 27, 2026 — VolitionRx updates on feline lymphoma milestone, licensing talks with over a dozen companies, and progress in cancer and sepsis diagnostics. Learn about Nu.Q, Capture-Seq, and lung cancer assay reimbursement.
May 27, 2026 — Cardio Diagnostics (CDIO) to exhibit AI-powered cardiovascular risk assessments at benefits conferences, targeting employer health plan cost reduction.
May 27, 2026 — Tonix Pharmaceuticals announces publication of Phase 1 data for TNX-1500 in Journal of Clinical Immunology, showing safety and tolerability, supporting advancement to Phase 2 kidney transplant rejection study.
May 27, 2026 — TransCode Therapeutics announces Phase 2a trial of TTX-MC138 in colorectal cancer patients with minimal residual disease, targeting microRNA-10b to reduce recurrence risk.
May 27, 2026 — GeoVax CEO David Dodd to present on resilient infectious disease preparedness strategy using MVA-based vaccine technologies in May 28 webinar. Learn about platform-based solutions for Ebola, Marburg, Hantavirus, Mpox threats.
May 27, 2026 — ioTech International launches ioBrite Gentle, a zero-sensitivity teeth whitening kit that avoids peroxide-heavy formulas, offering professional-strength whitening without tooth sensitivity or gum irritation.
May 27, 2026 — Study in Journal of the American Heart Association finds that high heart health scores, using Life's Essential 8, reduce risk of severe COVID-19 hospitalization or death by 46%.
May 26, 2026 — Regentis Biomaterials (RGNT) advances GelrinC, an off-the-shelf hydrogel for knee cartilage repair, with FDA trial enrollment over 50% and a 400% production yield boost.
May 26, 2026 — HeartBeam (NASDAQ: BEAT) develops cable-free, portable 12-lead ECG system to address pre-hospital delay in cardiac care. FDA-cleared for arrhythmia, with heart attack detection planned.
May 26, 2026 — Visory Health promotes Alexandra Robertson to Chief Growth Officer and Brittney Tierce to Chief Technology Officer. The prescription discount card platform expands access to affordable medications for Veterans and underserved communities.
May 26, 2026 — Onco-Innovations reports progress in manufacturing ONC010, a nanoparticle oncology candidate targeting solid tumors. The company advances IND-enabling work with Dalton Pharma Services.
May 26, 2026 — Redwood AI collaborates with Resilience Biosciences to use AI-assisted computational chemistry for non-opioid drug development, aiming to accelerate discovery of safer pain therapies.
May 26, 2026 — NanoViricides proposes NV-387 for Bundibugyo Ebola strain with no approved treatments. Oral formulation and Phase II trial for mpox may accelerate availability. Learn more about NNVC.
May 26, 2026 — A Karolinska Institutet study finds sexual difficulties common among young cancer survivors, varying by cancer type and treatment intensity. CNS Pharmaceuticals works on safer brain cancer drugs. Learn more at TinyGems.
May 26, 2026 — Tonix Pharmaceuticals presents real-world data at ISPOR showing high comorbidity and cost burden of fibromyalgia, as TONMYA launch approaches. Read more at InvestorWire.
May 26, 2026 — Annovis Bio regains NYSE compliance, continuing trading under ANVS. The biotech advances buntanetap for Alzheimer's and Parkinson's diseases, targeting neurotoxic proteins to halt neurodegeneration.
May 26, 2026 — Oncotelic Therapeutics (OTLC) completes $12.5M monetization of N2B CNS delivery system with Lunai Bioworks for Alzheimer's and biodefense. CNS drug delivery breakthroughs drive biotech market opportunities.
May 26, 2026 — GeoVax prioritizes GEO-MVA mpox/smallpox vaccine and Gedeptin cancer therapy, discontinues COVID-19 vaccine. Strategic focus on expedited regulatory paths and commercialization.
May 22, 2026 — NeuroOne Medical Technologies restates Q2 2026 results due to revenue overstatement of $0.5M, but reaffirms FY2026 revenue guidance of at least $10.5M. CEO Dave Rosa emphasizes one-time correction.
May 22, 2026 — Helix BioPharma grants 1.3M stock options at $1.63 per share, cancels 2.2M options previously granted. The company advances oncology pipeline with L-DOS47 and GEMCEDA.